Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
Status:
Withdrawn
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study of intravenous Bevacizumab in patients with pathologically confirmed
nonresectable primary adrenocortical cancer (ACC). Patients must have received no prior
therapy. They will receive Bevacizumab as a single agent every 2 weeks intravenously until
disease progression. This study will be open at multiple sites.